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Abstract
The European Commission mandated EFSA to review a new data package provided by the company
Elanco, for the possible integration/non-integration of the DNA plasmid vaccine CLYNAV into the genome
of Atlantic salmon (Salmo salar) and to indicate whether EFSA agrees with the conclusions drawn by
Elanco. The vaccine is injected into ﬁsh to confer protection against pancreas disease caused by the
salmonid alphavirus. The majority of the experimental data provided by the company was for muscle
tissue close to the injection site and for gonadal tissue. EFSA considers that the long persistence of DNA
plasmid in muscle tissue close to the injection site and the potential heritability of an integration event in
gonad cells support the focus of the assessment on both these tissues. The experimental data did not
provide scientiﬁcally robust evidence for a true integration event. The company overall concluded that
the likelihood of integration is negligible, based on considerations in the context of the company’s
environmental risk assessment, but did not provide a quantitative value for the rate of integration linked
to the term ‘negligible’. It is therefore not possible to evaluate this statement speciﬁcally with regard to
integration rates. EFSA notes that knowledge about homologous and non-homologous integration
predicts that integration could occur with certain frequency. Therefore, EFSA has constructed worst-case
scenarios leading to upper estimates for possible integration rates of the DNA plasmid vaccine into the
Atlantic salmon genome. EFSA concludes that, based on the worst-case scenarios described here and
taking into account additional factors decreasing the likelihood of integration, the actual integration rate
is likely to be orders of magnitude lower than the upper estimated integration rate calculated in the
context of the worst-case scenarios. With the available evidence, the actual integration rate cannot be
estimated with more precision.
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